3 results
Approved WMOCompleted
To determine the conversion rate of PR to CR (i.e. PET negativity) after a single dose of 90Y-ibritumomab tiuxetan (a dose of 14.8 MBq/kg or 0.4 mCi/kg, max 1184 MBq or 32mCi) in patients with grade 1-3a, stage II, III or IV follicular lymphoma with…
Approved WMOCompleted
The study consists of and endoscopic part (1) and an intraoperative part (2).1) Endoscopic part: to determine the feasibility and safety of molecular fluorescence endoscopy using the fluorescent tracer cetuximab-IRDye800CW targeting the epidermal…
Approved WMORecruiting
To establish that recovery time from a bronchoprofocation test is faster with HFNC compared to no interfention